WO2002047723A1 - Compositions medicamenteuses presentant une meilleure hydrosolubilite - Google Patents

Compositions medicamenteuses presentant une meilleure hydrosolubilite Download PDF

Info

Publication number
WO2002047723A1
WO2002047723A1 PCT/JP2001/010829 JP0110829W WO0247723A1 WO 2002047723 A1 WO2002047723 A1 WO 2002047723A1 JP 0110829 W JP0110829 W JP 0110829W WO 0247723 A1 WO0247723 A1 WO 0247723A1
Authority
WO
WIPO (PCT)
Prior art keywords
solubility
improved water
medicinal compositions
retracting
substance
Prior art date
Application number
PCT/JP2001/010829
Other languages
English (en)
Japanese (ja)
Inventor
Yohko Akiyama
Hiroto Bando
Yukihiro Matsumoto
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2002221116A priority Critical patent/AU2002221116A1/en
Publication of WO2002047723A1 publication Critical patent/WO2002047723A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Abstract

L'invention concerne des dispersions solides contenant une substance hydrosoluble à rétraction de plaques riches en lipides et un polymère hydrophobe. Ces dispersions présente une meilleure solubilité de la substance hydrosoluble à rétraction de plaques riches en lipides, une meilleure absorbabilité par voie orale, et une meilleure absorbabilité dans le sang.
PCT/JP2001/010829 2000-12-11 2001-12-11 Compositions medicamenteuses presentant une meilleure hydrosolubilite WO2002047723A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221116A AU2002221116A1 (en) 2000-12-11 2001-12-11 Medicinal compositions having improved water-solubility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375604 2000-12-11
JP2000-375604 2000-12-11

Publications (1)

Publication Number Publication Date
WO2002047723A1 true WO2002047723A1 (fr) 2002-06-20

Family

ID=18844593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010829 WO2002047723A1 (fr) 2000-12-11 2001-12-11 Compositions medicamenteuses presentant une meilleure hydrosolubilite

Country Status (2)

Country Link
AU (1) AU2002221116A1 (fr)
WO (1) WO2002047723A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471064A1 (fr) * 2002-01-11 2004-10-27 Takeda Chemical Industries, Ltd. Derives de coumarine, leur procede de production et d'utilisation
US7553973B2 (en) 2005-03-23 2009-06-30 Merck Frosst Canada Ltd. Pharmaceutical compounds
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585913A2 (fr) * 1992-09-04 1994-03-09 Takeda Chemical Industries, Ltd. Composés hétérocycliques condensés, leur production et usage
EP0602598A1 (fr) * 1992-12-16 1994-06-22 Takeda Chemical Industries, Ltd. Anilides de l'acide 3-phénylindolyl-,-benzofurannyl- et benzothiénylalkyl carboxylique, leur préparation et utilisation
EP0613894A1 (fr) * 1993-02-27 1994-09-07 Nihon Nohyaku Co., Ltd. Dérivés de N-heteroaryl-N-phénylurée, leur préparation et utilisation
JPH06263736A (ja) * 1993-01-14 1994-09-20 Takeda Chem Ind Ltd 含窒素縮合複素環化合物、その製造法及び剤
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
WO1995014463A1 (fr) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition de preparation pharmaceutique a absorption perorale amelioree
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
WO1998001122A1 (fr) * 1996-07-08 1998-01-15 Kyowa Hakko Kogyo Co., Ltd. Dispersions solides ou preparations de dispersions solides a base de composes tricycliques
EP0842659A1 (fr) * 1996-11-15 1998-05-20 Pfizer Inc. Utilisation d'agonistes/antagonistes d'oestrogène pour fabriquer un médicament pour traiter l'athérosclérose
EP0842661A2 (fr) * 1996-11-15 1998-05-20 Pfizer Inc. Traitement de l'athérosclerose
EP0843999A1 (fr) * 1996-11-15 1998-05-27 Pfizer Inc. Utilisation d'agonistes/antagonistes d'oestrogène dans la fabrication d'un médicament pour le traitement de l'athérosclérose indépendant d'un effet de baisse des lipides
JPH10306078A (ja) * 1997-05-08 1998-11-17 Mitsubishi Chem Corp ウレア誘導体
WO1999033825A1 (fr) * 1997-12-23 1999-07-08 Merck Patent Gmbh Derives n-phenylamides et n-pyridylamides, procede de preparation correspondant et compositions pharmaceutiques contenant ces composes
WO2002006264A1 (fr) * 2000-07-13 2002-01-24 Takeda Chemical Industries, Ltd. Inhibiteurs de plaques riches en lipide

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
EP0585913A2 (fr) * 1992-09-04 1994-03-09 Takeda Chemical Industries, Ltd. Composés hétérocycliques condensés, leur production et usage
EP0602598A1 (fr) * 1992-12-16 1994-06-22 Takeda Chemical Industries, Ltd. Anilides de l'acide 3-phénylindolyl-,-benzofurannyl- et benzothiénylalkyl carboxylique, leur préparation et utilisation
JPH06263736A (ja) * 1993-01-14 1994-09-20 Takeda Chem Ind Ltd 含窒素縮合複素環化合物、その製造法及び剤
EP0613894A1 (fr) * 1993-02-27 1994-09-07 Nihon Nohyaku Co., Ltd. Dérivés de N-heteroaryl-N-phénylurée, leur préparation et utilisation
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
WO1995014463A1 (fr) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition de preparation pharmaceutique a absorption perorale amelioree
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
WO1998001122A1 (fr) * 1996-07-08 1998-01-15 Kyowa Hakko Kogyo Co., Ltd. Dispersions solides ou preparations de dispersions solides a base de composes tricycliques
EP0842659A1 (fr) * 1996-11-15 1998-05-20 Pfizer Inc. Utilisation d'agonistes/antagonistes d'oestrogène pour fabriquer un médicament pour traiter l'athérosclérose
EP0842661A2 (fr) * 1996-11-15 1998-05-20 Pfizer Inc. Traitement de l'athérosclerose
EP0843999A1 (fr) * 1996-11-15 1998-05-27 Pfizer Inc. Utilisation d'agonistes/antagonistes d'oestrogène dans la fabrication d'un médicament pour le traitement de l'athérosclérose indépendant d'un effet de baisse des lipides
JPH10306078A (ja) * 1997-05-08 1998-11-17 Mitsubishi Chem Corp ウレア誘導体
WO1999033825A1 (fr) * 1997-12-23 1999-07-08 Merck Patent Gmbh Derives n-phenylamides et n-pyridylamides, procede de preparation correspondant et compositions pharmaceutiques contenant ces composes
WO2002006264A1 (fr) * 2000-07-13 2002-01-24 Takeda Chemical Industries, Ltd. Inhibiteurs de plaques riches en lipide

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471064A1 (fr) * 2002-01-11 2004-10-27 Takeda Chemical Industries, Ltd. Derives de coumarine, leur procede de production et d'utilisation
EP1471064A4 (fr) * 2002-01-11 2005-04-27 Takeda Pharmaceutical Derives de coumarine, leur procede de production et d'utilisation
US7553973B2 (en) 2005-03-23 2009-06-30 Merck Frosst Canada Ltd. Pharmaceutical compounds
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Also Published As

Publication number Publication date
AU2002221116A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
WO2002048141A1 (fr) Composition medicinale dont la solubilite dans l'eau est amelioree
EP1364643A4 (fr) Composition a solubilite ou absorbabilite orale amelioree
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
AU2002239397A1 (en) Drug formulation having improved oral tolerability
IL156531A0 (en) Lipid nanoparticles, their preparation and pharmaceutical compositions containing them
IL144501A0 (en) Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
WO2001087264A3 (fr) Forme galenique orale solide a desintegration rapide
WO1999039694A3 (fr) Compositions contenant des composes organiques
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2001272314A1 (en) Oral formulations for localized colonic release and the method of preparation thereof
CA2388322A1 (fr) Composition pharmaceutique a base de ciclesonide destinee a la muqueuse
WO2003018064A3 (fr) Compositions de medicaments lipophiles
WO2002047723A1 (fr) Compositions medicamenteuses presentant une meilleure hydrosolubilite
AU2001252711A1 (en) Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
WO1999047172A3 (fr) Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion
HK1056564A1 (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof.
AU6601900A (en) Silicon derivatives of fragrant, flavouring and medicinal substances
AU6423600A (en) The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof
CA2376847A1 (fr) Complexe d'eletriptan et de derive de cyclodextrine
AU4671701A (en) Medical compositions comprising (r,r)-formoterol and rofleponide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP